Highlights

Simons Trading Research

Author: simonsg   |   Latest post: Wed, 26 Feb 2020, 3:51 PM

 

UG Healthcare - Capacity Rise Delay, Valuation Attractive; BUY

Author:   |    Publish date:


  • Reiterate BUY with new SGD0.30 Target Price from SGD0.32, 67% upside.
  • Our Target Price is pegged to 11x FY20F (Jun) EPS, which is at a discount to the 19x peer average, factoring in UG Healthcare’s relatively smaller production output.
  • Whilst FY19 net profit disappointed, the 47% y-o-y rise in gross profit reflects strength. We believe continued growth in gross margin will strengthen FY20 earnings.

FY19 Revenue and Gross Profit Rose

  • UG HEALTHCARE (SGX:41A)'s FY19 full-year revenue was up 17% y-o-y. The new production facility – which achieved full commercialisation at end January – led to additional annual capacity of 500m pieces of gloves. There was overall production efficiency and economies of scale, which contributed to the 47% y-o-y rise in FY19 gross profit.
  • GPM rose 4ppts to 20.4% for the full year. Management sees GPM rising further over the next few years on economies of scale.

Weak 4QFY19 Net Profit Despite Higher Revenue

  • UG Healthcare’s earnings for this period stood at SGD0.54m (-59% y-o-y), mainly due to higher marketing, distribution, administrative, and finance expenses. This was on top of 4QFY19 revenue rising 20% y-o-y.
  • With the Jul 2018 consolidation of its Brazilian subsidiary, costs rose. However, goods sold from parent to subsidiary are not factored as group revenue – unless sold to end customers. This led to 4QFY19 reporting net profit being SGD0.6m weaker.

Slight Delay in Increasing Production Capacity

  • Given the ongoing macroeconomic uncertainties, UG Healthcare has postponed – slightly – the initial timing to increase production capacity by another 300m gloves annually. The 3.2bn gloves pa capacity target should now be achieved in FY21 instead of FY20.
  • For FY20F, UG Healthcare will upgrade some of its existing production lines to further enhance production efficiency and economies of scale.

FY19 Final Dividend of 0.259 Cents/share

  • The company is recommending a FY19 final dividend of 0.259 cents/share. This translates into a payout ratio of 20%. Shareholders have the option of receiving the dividend in scrip or cash. See UG Healthcare's dividend history.

Our Target Price Is Pegged to 11x FY20F EPS

  • Our Target Price is pegged to 1119x – this factors in UG Healthcare’s much smaller production output vs peers, most of which are listed on Bursa Malaysia.
  • We cut FY20F net profit 13% to SGD5.3m while raising FY20F revenue 9% – this was offset by increased marketing and administrative expenses.
  • Key risks include higher gas and raw material prices, which could narrow margins going forward.

Source: RHB Invest Research - 28 Aug 2019

Share this

Related Stocks

Chart Stock Name Last Change Volume 
UG Healthcare 0.23 -0.005 (2.13%) 1,635 

  Be the first to like this.
 


 

119  165  161  658 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 Rex Intl 0.199+0.004 
 Genting Sing 0.83-0.01 
 SingTel 3.07-0.01 
 BreadTalk 0.76+0.115 
 Golden Agri-Res 0.2050.00 
 Amplefield Ltd 0.046+0.002 
 AusGroup^ 0.0440.00 
 YZJ Shipbldg SGD 0.975+0.005 
 Mapletree Com Tr 2.20-0.03 
 Net Pacific Fin 0.025+0.001 
Partners & Brokers